OrthoPediatrics Corp. (NASDAQ:KIDS) Receives Average Recommendation of “Buy” from Brokerages

OrthoPediatrics Corp. (NASDAQ:KIDSGet Rating) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $63.80.

Several research analysts have recently commented on KIDS shares. Zacks Investment Research raised OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Tuesday. Truist Financial decreased their price objective on OrthoPediatrics from $70.00 to $54.00 in a research note on Friday, May 6th. Needham & Company LLC decreased their price objective on OrthoPediatrics from $83.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, March 3rd. Piper Sandler decreased their price objective on OrthoPediatrics from $80.00 to $55.00 in a research note on Thursday, May 5th. Finally, TheStreet downgraded OrthoPediatrics from a “c” rating to a “d+” rating in a research note on Thursday, May 5th.

Shares of NASDAQ:KIDS opened at $43.23 on Friday. The stock has a market capitalization of $874.54 million, a price-to-earnings ratio of -56.14 and a beta of 0.88. The stock’s 50-day simple moving average is $48.70 and its two-hundred day simple moving average is $53.23. OrthoPediatrics has a 52-week low of $36.71 and a 52-week high of $73.91.

OrthoPediatrics (NASDAQ:KIDSGet Rating) last announced its earnings results on Wednesday, March 2nd. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.05. The business had revenue of $24.81 million for the quarter, compared to analysts’ expectations of $24.78 million. OrthoPediatrics had a negative return on equity of 7.04% and a negative net margin of 14.98%. During the same period last year, the firm posted ($0.31) earnings per share. As a group, equities analysts forecast that OrthoPediatrics will post -0.79 earnings per share for the current year.

In other OrthoPediatrics news, CFO Fred Hite sold 4,919 shares of OrthoPediatrics stock in a transaction that occurred on Wednesday, March 2nd. The stock was sold at an average price of $57.48, for a total value of $282,744.12. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gregory A. Odle sold 4,108 shares of OrthoPediatrics stock in a transaction that occurred on Wednesday, March 2nd. The stock was sold at an average price of $57.55, for a total value of $236,415.40. The disclosure for this sale can be found here. Insiders have sold a total of 22,984 shares of company stock worth $1,334,452 in the last three months. 30.30% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd bought a new stake in OrthoPediatrics in the 1st quarter worth approximately $26,000. United Capital Financial Advisers LLC increased its stake in OrthoPediatrics by 7.4% in the 1st quarter. United Capital Financial Advisers LLC now owns 59,946 shares of the company’s stock worth $3,236,000 after acquiring an additional 4,147 shares during the last quarter. Graham Capital Management L.P. bought a new stake in OrthoPediatrics in the 1st quarter worth approximately $410,000. Invesco Ltd. increased its stake in OrthoPediatrics by 9.3% in the 1st quarter. Invesco Ltd. now owns 455,486 shares of the company’s stock worth $24,593,000 after acquiring an additional 38,638 shares during the last quarter. Finally, Granahan Investment Management LLC increased its stake in OrthoPediatrics by 44.2% in the 1st quarter. Granahan Investment Management LLC now owns 374,867 shares of the company’s stock worth $20,239,000 after acquiring an additional 114,844 shares during the last quarter. 71.51% of the stock is currently owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile (Get Rating)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

Featured Stories

Analyst Recommendations for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.